secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001628280-24-033874
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q2 net loss narrows to $17.7M; cash $295.7M; CFT1946 ESMO data Sept 14
--------------------------------------------------------------------------------

- Revenue $12.0M vs $2.7M YoY, driven by $8M Biogen milestone.
- Net loss $17.7M ($0.26 per share) vs $35.9M ($0.73) in Q2 2023.
- Cash $295.7M; expects runway into 2027.
- CFT1946 Phase 1 monotherapy data to be presented at ESMO Congress 2024 on Sept 14.
- Cemsidomide Phase 1 data in MM and NHL on track for Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024033874/0001628280-24-033874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024033874/cccc-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-033874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer